AVR

8.35%

$9.99 anteris technologies ltd

Why don't the board buy on market to instill confidence in the...

First 4 Last

Share
Profile

Follow
lexcorp

8,030 Posts.

520

03/06/21

15:10

Post #: 53625620
Share

Originally posted by Eire2011 ↑

If anyone would like to propose a question to the company for the AGM I would be happy to collate them and forward them on. There is no guarantee these questions will be reviewed or answered but it would be good to present them to the company in any case.

I will kick off proceedings with a few questions of my own, some I know the answers to but would be good to be address for those that do less research:

When can you expect to do a licensing deal and receive licence fees implied in MST report?

If AVR need to go it alone how will you secure capital for this?

When raising capital why do retail holders not get an option to participate?

When will AVR finally take away the worries about capital restraint issues that have plagued the company for so long?

Why can you not use the Mercer funds and when will it make sense to do so?

Can we have an update on the CABG opportunity and progress in the proof of concept studies? How big is this market opportunity?

Is Resilia real competition for Adapt? Any comment about this tissue also not being stored in glutaraltehyde?

When you expect the SAVR trial to conclude with COVID improving in Europe?

Will you apply for Breakthroug Status before or after the FIH trial?

Will you have any FIH TAVR patients completed before the options expire?

It is important that the December dates $8 options get exercised, does the company have sufficient market sensitive news flow planned to ensure a high enough share price to achieve this?

Of the three key innovations (Adapt, DurAVR and ComASUR) which is more unique, innovative and most important to lure Drs to swap their TAVR of choice? Or is it the combination of the three that really makes it a winner.

Assuming we try for CE Mark before FDA approval, when is the earliest you can envisage a DurAVR TAVR being able to be sold into that market?

Do you think we are more likely to A be acquired, B be partnered or C Go it alone?

What other Adapt related opportunities are their on the horizon when and if we have capital to develop them?

Can you please give an update on 4C Medical and their exciting TMVR progress using adapt tissue in their device?

Can the company please make an effort to update the company more through the ASX than Twitter and can we have more regular investor presentations released to better inform investors of the opportunity before the company?

That’s a start but please feel free to add well thought through questions below.

Expand

Why don't the board buy on market to instill confidence in the shareholder base?

AVR Price at posting: $7.91 Sentiment: Buy Disclosure: Held
9 Upvote

0 Great analysis

Reply

Top Stories

BIT

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

LAM

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

OCC

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

RMX

Red Mountain Mining: record gold prices, two projects, two greenstone belts

As Nvidia cools, we're looking to Aussie AI

CBA breaks trading record on strong day for Aussie financials

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

QML

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

SBW

Shekel Brainweigh investor presentation webinar – the future of retail automation

PRU

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

There are more pages in this discussion • 26 more messages in this thread...

First 4 Last

Add AVR (ASX) to my watchlist

(20min delay)
Last $9.99		Change -0.910(8.35%)		Mkt cap ! $211.1M

Open	High	Low	Value	Volume
$10.50	$10.79	$9.30	$1.477M	149.3K

Buyers (Bids)

No.	Vol.	Price($)
1	2000	$9.70

Sellers (Offers)

Price($)	Vol.	No.
$9.99	1999	1

View Market Depth

No.	Vol.	Price($)
1	60	9.600
1	1050	9.500
1	1050	9.400
2	1060	9.350
2	585	9.300

Price($)	Vol.	No.
10.000	493	1
10.300	1000	1
10.450	357	1
10.900	1500	1
11.000	13000	2

Last trade - 16.10pm 06/09/2024 (20 minute delay)

AVR (ASX) Chart

Why don't the board buy on market to instill confidence in the...

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

Red Mountain Mining: record gold prices, two projects, two greenstone belts

As Nvidia cools, we're looking to Aussie AI

CBA breaks trading record on strong day for Aussie financials

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Shekel Brainweigh investor presentation webinar – the future of retail automation

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Why don't the board buy on market to instill confidence in the...

Top Stories

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

Red Mountain Mining: record gold prices, two projects, two greenstone belts

As Nvidia cools, we're looking to Aussie AI

CBA breaks trading record on strong day for Aussie financials

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Shekel Brainweigh investor presentation webinar – the future of retail automation

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News